Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,802.00
Bid: 1,802.00
Ask: 1,804.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.111%)
Open: 1,780.00
High: 1,814.00
Low: 1,780.00
Prev. Close: 1,802.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Genus Chief Executive Transition

25 Mar 2019 07:00

RNS Number : 8056T
Genus PLC
25 March 2019
 

For Immediate Release 25 March 2019

 

Genus plc('Genus', or the 'Company')

Genus Chief Executive Transition

Genus plc (LSE: GNS), a leading global animal genetics company, announces that Karim Bitar, Chief Executive Officer, will be stepping down from the Board from 16 September 2019. Karim will be taking the Chief Executive Officer position at ConvaTec Group Plc from 30 September 2019. Karim has committed to remain with Genus and continue in his role until 16 September, to achieve an orderly succession and transition process, while continuing to drive business performance.

"During Karim's eight years at Genus as Chief Executive, the Company has been transformed into a world-leading animal genetics company, truly fulfilling its vision to pioneer animal genetic improvement to help nourish the world. He has led the Company's transformation and is leaving the Company in excellent shape with a world-class leadership team, world-class genetics and innovative technology platforms to enable us to pursue many exciting global opportunities," said Bob Lawson Chair of Genus. "His legacy is the creation of an outstanding global team that will sustain the Company's growth, while serving customers with an unparalleled range of products and services. Karim has provided the Company with many years of strong leadership, and the Board and I remain excited by the Company's future prospects. On behalf of the Board and all at Genus, I wish Karim well for the future and thank him for his considerable contribution during his time with the Company."

Karim Bitar said "It has been a great privilege to lead such a talented group of people and develop a leading global agricultural biotechnology company focused on animal genetics. Genus is in a very strong strategic and financial position, with significant growth prospects and I will miss the team tremendously when I eventually leave in September."

The Board has commenced a search to identify his successor and a further announcement will be made in due course. 

For further information please contact:

Genus

Tel: +44(0)1256 345970

Bob Lawson, Chair

 

Stephen Wilson, Group Finance Director

 

Buchanan

Tel: +44(0)207 466 5000

Charles Ryland /Chris Lane/Sophie Wills

 

This announcement is available on the Genus website www.genusplc.com

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Regulatory Notes

Details of Karim Bitar's terms of departure are still to be finalised. Any such terms will be consistent with the Company's approved Directors Remuneration Policy. Details of any payments to be made to Karim will be posted on the Company's website, in accordance with section 430(2B) Companies Act 2006. This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014. The person responsible for making this announcement on behalf of the Group is Dan Hartley (General Counsel and Company Secretary).

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPGUMGWUPBGBC
Date   Source Headline
8th Jul 20143:34 pmRNSHolding(s) in Company
7th Jul 20148:42 amRNSHolding(s) in Company
4th Jul 20141:43 pmRNSHolding(s) in Company
2nd Jul 20145:03 pmRNSHolding(s) in Company
1st Jul 201410:00 amRNSTotal Voting Rights
9th Jun 20142:00 pmRNSCompany Secretary Change
27th May 20147:00 amRNSUpdate on Shennong Joint Venture in China
15th May 20147:00 amRNSInterim Management Statement
15th May 20147:00 amRNSStrategic Beef Partnership with ABP Food Group
3rd Apr 20144:29 pmRNSDirector/PDMR Shareholding
28th Mar 20142:22 pmRNSDirector/PDMR Shareholding
19th Mar 20144:05 pmRNSBoard Appointments
17th Mar 20144:35 pmRNSDirector/PDMR Shareholding
25th Feb 20147:00 amRNSInterim Results
10th Feb 20147:00 amRNSCompletion of Acquisition of Genetiporc do Brasil
31st Jan 20142:00 pmRNSBlocklisting Interim Review
31st Jan 20142:00 pmRNSTotal Voting Rights
31st Dec 201312:41 pmRNSTotal Voting Rights
31st Dec 201312:41 pmRNSDirector/PDMR Shareholding
12th Dec 20133:00 pmRNSDirector/PDMR Shareholding
29th Nov 20135:01 pmRNSTotal Voting Rights
15th Nov 20133:02 pmRNSResult of AGM
15th Nov 20137:00 amRNSInterim Management Statement
31st Oct 20134:25 pmRNSTotal Voting Rights
29th Oct 20132:30 pmRNSHolding(s) in Company
18th Oct 20137:00 amRNSCompletion of Acquisition of Génétiporc
10th Oct 20134:35 pmRNSAnnual Report & Annual General Meeting
3rd Oct 20132:00 pmRNSAdditional Listing
2nd Oct 20135:00 pmRNSTotal Voting Rights
27th Sep 20136:19 pmRNSDirector/PDMR Shareholding
23rd Sep 20137:00 amRNSGenus to Acquire Génétiporc
3rd Sep 20133:04 pmRNSCorrection of Record Date
3rd Sep 20137:00 amRNSPreliminary Results
31st Jul 20133:00 pmRNSBlocklisting Interim Review
25th Jul 201310:14 amRNSCompany Secretary Appointment
18th Jul 20139:00 amRNSHolding(s) in Company
11th Jun 20135:07 pmRNSHolding(s) in Company
4th Jun 20139:10 amRNSHolding(s) in Company
31st May 20132:00 pmRNSTotal Voting Rights
23rd May 20138:22 amRNSDirector/PDMR Shareholding
21st May 20134:56 pmRNSHolding(s) in Company
30th Apr 20137:00 amRNSInterim Management Statement
8th Apr 20136:09 pmRNSHolding(s) in Company
8th Apr 201310:27 amRNSHolding(s) in Company
28th Mar 20134:13 pmRNSHolding(s) in Company
28th Mar 20133:51 pmRNSTotal Voting Rights
21st Mar 20132:00 pmRNSHolding(s) in Company
11th Mar 20134:07 pmRNSDirector/PDMR Shareholding
4th Mar 20132:00 pmRNSHolding(s) in Company
28th Feb 20132:30 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.